Gongwin Biopharm Holdings Co., Ltd. (TPEX:6617)
Taiwan · Delayed Price · Currency is TWD 134.50
-0.50 (-0.37%)
Sep 8, 2026, 1:00 PM CST
Gongwin Biopharm Holdings Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 42.22 | 36.45 | 32.04 | 18.92 | 1.14 | 1.14 | |
Revenue Growth | 22.49% | 13.75% | 69.39% | 1554.86% | 0% | 37.21% |
Cost of Revenue | 15.59 | 10.36 | 23.36 | 7.72 | 0.08 | 0.07 |
Gross Profit | 26.64 | 26.09 | 8.68 | 11.2 | 1.07 | 1.08 |
Selling, General & Admin | 143.35 | 115.55 | 101.56 | 91.88 | 67.43 | 38.85 |
Research & Development | 125.93 | 119.47 | 63.27 | 52.65 | 194.32 | 83.05 |
Operating Expenses | 267.81 | 233.38 | 170.74 | 144.53 | 261.75 | 121.9 |
Operating Income | -241.17 | -207.29 | -162.06 | -133.33 | -260.68 | -120.83 |
Interest Expense | -4.08 | -5.15 | -4.3 | -7.19 | -3.19 | -1.18 |
Interest & Investment Income | 55.13 | 70.81 | 64.62 | 41.61 | 6.82 | 2.4 |
Currency Exchange Gain (Loss) | -1.46 | -1.46 | -4.69 | -4.85 | -39.6 | 0.9 |
Other Non Operating Income (Expenses) | -3.67 | 3.09 | 3.47 | 2.58 | 4.51 | 2.05 |
EBT Excluding Unusual Items | -195.25 | -140 | -102.96 | -101.18 | -292.13 | -116.66 |
Gain (Loss) on Sale of Investments | 19.21 | 19.21 | 11.11 | - | - | 0.74 |
Gain (Loss) on Sale of Assets | -0.08 | -0.08 | -0 | - | - | - |
Other Unusual Items | - | - | - | - | - | 1.2 |
Pretax Income | -176.12 | -120.87 | -91.86 | -101.18 | -292.13 | -114.72 |
Income Tax Expense | 0.05 | 0.16 | 0.13 | - | - | 15.2 |
Earnings From Continuing Operations | -176.17 | -121.03 | -91.99 | -101.18 | -292.13 | -129.92 |
Minority Interest in Earnings | 11.65 | 6.9 | 9.44 | 9.14 | - | 8.34 |
Net Income | -164.52 | -114.13 | -82.55 | -92.04 | -292.13 | -121.58 |
Net Income to Common | -164.52 | -114.13 | -82.55 | -92.04 | -292.13 | -121.58 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 121 | 123 | 121 | 113 | 111 | 110 |
Shares Outstanding (Diluted) | 121 | 123 | 121 | 113 | 111 | 110 |
Shares Change | -3.39% | 2.19% | 6.64% | 1.92% | 1.44% | 4.87% |
EPS (Basic) | -1.35 | -0.92 | -0.68 | -0.81 | -2.63 | -1.11 |
EPS (Diluted) | -1.35 | -0.92 | -0.68 | -0.81 | -2.63 | -1.11 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -198.28 | -137.62 | -293.3 | -111.7 | -239.54 | -218.52 |
Free Cash Flow Per Share | -1.63 | -1.11 | -2.43 | -0.99 | -2.15 | -2.00 |
Gross Margin | 63.09% | 71.58% | 27.09% | 59.21% | 93.26% | 94.31% |
Operating Margin | -571.17% | -568.76% | -505.80% | -704.87% | -22806.74% | -10570.95% |
Profit Margin | -389.63% | -313.14% | -257.64% | -486.58% | -25558.44% | -10637.01% |
Free Cash Flow Margin | -469.60% | -377.59% | -915.41% | -590.55% | -20956.69% | -19118.11% |
EBITDA | -232.57 | -198.59 | -153.87 | -125.03 | -252.2 | -112.82 |
D&A For EBITDA | 8.6 | 8.7 | 8.19 | 8.29 | 8.48 | 8 |
EBIT | -241.17 | -207.29 | -162.06 | -133.33 | -260.68 | -120.83 |